Tilray Brands, Inc.
General ticker "TLRY" information:
- Sector: Health Care
- Industry: Drug Manufacturers - Specialty & Generic
- Capitalization: $968.4M (TTM average)
Tilray Brands, Inc. does not follow the US Stock Market performance with the rate: -22.4%.
Estimated limits based on current volatility of 4.0%: low 3.95$, high 4.28$
Factors to consider:
- Total employees count: 2842 (+7.2%) as of 2025
- US accounted for 29.6% of revenue in the fiscal year ended 2024-05-31
- Top business risk factors: Regulatory and compliance, Crop failure, Security breaches, Market demand, Profitability
- Price in estimated range
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-05-31 to 2027-05-31
- 2025-05-31 to 2026-05-31 estimated range: [2.34$, 7.62$]
- 2026-05-31 to 2027-05-31 estimated range: [1.75$, 5.52$]
Financial Metrics affecting the TLRY estimates:
- Positive: with PPE of -20.3 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -23.84 <= 0.30
- Negative: negative Net income
- Negative: Inventory ratio change, % of 0.82 > 0.80
- Negative: negative Industry operating cash flow (median)
- Negative: Investing cash flow per share per price, % of -11.77 <= -4.44
- Positive: Industry inventory ratio change (median), % of -0.37 <= -0.15
- Negative: Industry earnings per price (median), % of 0 <= 0
Short-term TLRY quotes
Long-term TLRY plot with estimates
Financial data
| YTD | 2023-05-31 | 2024-05-31 | 2025-05-31 |
|---|---|---|---|
| Operating Revenue | $627.12MM | $788.94MM | $821.31MM |
| Operating Expenses | $1,996.81MM | $1,000.12MM | $3,104.01MM |
| Operating Income | $-1,369.68MM | $-211.18MM | $-2,282.70MM |
| Non-Operating Income | $-80.50MM | $-37.84MM | $-19.67MM |
| Interest Expense | $62.79MM | $67.13MM | $56.71MM |
| R&D Expense | $0.92MM | $0.87MM | $0.39MM |
| Income(Loss) | $-1,450.18MM | $-249.02MM | $-2,302.37MM |
| Taxes | $-7.18MM | $-26.62MM | $-121.02MM |
| Net Income(Loss)* | $-1,452.66MM | $-222.40MM | $-2,186.74MM |
| Stockholders Equity | $3,315.69MM | $3,442.91MM | $1,511.47MM |
| Inventory | $270.14MM | $343.49MM | $371.70MM |
| Assets | $4,307.26MM | $4,221.66MM | $2,074.33MM |
| Operating Cash Flow | $7.91MM | $-30.91MM | $-94.60MM |
| Capital expenditure | $28.02MM | $39.85MM | $45.17MM |
| Investing Cash Flow | $-285.11MM | $128.35MM | $-46.72MM |
| Financing Cash Flow | $70.16MM | $-75.19MM | $133.51MM |
| Earnings Per Share** | $-23.51 | $-2.99 | $-24.56 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.